Literature DB >> 20595157

Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach.

M Hoogendoorn1, R T Hoogenveen, M P Rutten-van Mölken, J Vestbo, T L Feenstra.   

Abstract

The aim of our study was to estimate the case fatality of a severe exacerbation from long-term survival data presented in the literature. A literature search identified studies reporting ≥1.5 yr survival after a severe chronic obstructive pulmonary disease (COPD) exacerbation resulting in hospitalisation. The survival curve of each study was divided into a critical and a stable period. Mortality during the stable period was then estimated by extrapolating the survival curve during the stable period back to the time of exacerbation onset. Case fatality was defined as the excess mortality that results from an exacerbation and was calculated as 1 minus the (backwardly) extrapolated survival during the stable period at the time of exacerbation onset. The 95% confidence intervals (CI) of the estimated case fatalities were obtained by bootstrapping. A random effect model was used to combine all estimates into a weighted average with 95% CI. The meta-analysis based on six studies that fulfilled the inclusion criteria resulted in a weighted average case-fatality rate of 15.6% (95% CI 10.9-20.3), ranging from 11.4% to 19.0% for the individual studies. A severe COPD exacerbation requiring hospitalisation not only results in higher mortality risks during hospitalisation, but also in the time-period after discharge and contributes substantially to total COPD mortality.

Entities:  

Mesh:

Year:  2010        PMID: 20595157     DOI: 10.1183/09031936.00043710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  45 in total

1.  Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Authors:  Ken M Kunisaki; Dennis E Niewoehner; John E Connett
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 2.  Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors:  Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

3.  [Outcome predictors for COPD patients hospitalized for acute exacerbation].

Authors:  M Spielmanns; F Axer; C Nell; A R Koczulla; T Boeselt; F Magnet; J H Storre; W Windisch
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-01-02       Impact factor: 0.840

Review 4.  Extracorporeal carbon dioxide removal in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Tommaso Pettenuzzo; Eddy Fan; Lorenzo Del Sorbo
Journal:  Ann Transl Med       Date:  2018-01

Review 5.  Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review.

Authors:  Michael C Sklar; Francois Beloncle; Christina M Katsios; Laurent Brochard; Jan O Friedrich
Journal:  Intensive Care Med       Date:  2015-06-25       Impact factor: 17.440

6.  Effectiveness and cost-effectiveness of early assisted discharge for chronic obstructive pulmonary disease exacerbations: the design of a randomised controlled trial.

Authors:  Cecile M A Utens; Lucas M A Goossens; Frank W J M Smeenk; Onno C P van Schayck; Walter van Litsenburg; Annet Janssen; Monique van Vliet; Wiel Seezink; Dirk R A J Demunck; Brigitte van de Pas; Peter J de Bruijn; Anouschka van der Pouw; Jeroen M A M Retera; Petra de Laat-Bierings; Loes van Eijsden; Maria Braken; Riet Eijsermans; Maureen P M H Rutten-van Mölken
Journal:  BMC Public Health       Date:  2010-10-18       Impact factor: 3.295

7.  A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD.

Authors:  Nausherwan K Burki; Raj Kumar Mani; Felix J F Herth; Werner Schmidt; Helmut Teschler; Frank Bonin; Heinrich Becker; Winfried J Randerath; Sven Stieglitz; Lars Hagmeyer; Christina Priegnitz; Michael Pfeifer; Stefan H Blaas; Christian Putensen; Nils Theuerkauf; Michael Quintel; Onnen Moerer
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

8.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.

Authors:  Samy Suissa; Sophie Dell'Aniello; Pierre Ernst
Journal:  Thorax       Date:  2012-06-08       Impact factor: 9.139

9.  Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.

Authors:  Stephen K Field
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2011-10-18

Review 10.  The role of bronchodilator treatment in the prevention of exacerbations of COPD.

Authors:  Jadwiga A Wedzicha; Marc Decramer; Terence A R Seemungal
Journal:  Eur Respir J       Date:  2012-07-26       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.